中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

13 records (took 0.023 seconds)

    Identification of adiponutrin-related proteins as esterases and methods of use for the same
    2.
    发明申请
    Identification of adiponutrin-related proteins as esterases and methods of use for the same 审中-公开
    脂肪素相关蛋白鉴定为酯酶及其使用方法

    公开(公告)号：US20070014776A1

    公开(公告)日：2007-01-18

    申请号：US11450935

    申请日：2006-06-09

    Applicant: Ruth Gimeno ,  Janet Paulsen ,  Jian-Liang Li ,  Andrew Lake ,  Wei Liu ,  Jae Eun Kim

    Inventor： Ruth Gimeno ,  Janet Paulsen ,  Jian-Liang Li ,  Andrew Lake ,  Wei Liu ,  Jae Eun Kim

    IPC: A61K38/54 ,  C12Q1/34 ,  C07H21/04 ,  C12P21/06 ,  C12N9/99

    CPC classification number: C12Q1/44 ,  A61K38/28 ,  C12N9/20 ,  G01N33/543 ,  G01N2333/918 ,  G01N2500/00 ,  G01N2800/04 ,  G01N2800/32

    Abstract: The present invention provides methods of identifying polypeptides that have enzymatic activity associated with nutrient and/or energy homeostasis, and thus, are involved in the development of one or more cardiovascular and metabolic disorders, e.g., cardiovascular disease, obesity, insulin resistance, type 2 diabetes, dyslipidemia, nonalcoholic fatty liver disease, and metabolic syndrome. One such method comprises identifying a polypeptide as a member of the adiponutrin family of proteins. As such, the invention is related to the polynucleotides and polypeptides belonging to the adiponutrin family, and provides novel isolated and purified polynucleotides and polypeptides of a novel member of the adiponutrin family, patatin-like phospholipase domain 1 (PNPLA1). Also provided are methods of using the polynucleotides and polypeptides related to or provided by the invention for screening a test compound, e.g., a small molecule, antibody, etc., for the ability of the test compound to detect and/or modulate the activity of one or more members of the adiponutrin family of proteins. The present invention also is directed to novel methods for diagnosing, prognosing, and monitoring the progress of at least one cardiovascular and metabolic disorder using polynucleotides or polypeptides belonging to the adiponutrin family, and/or modulators of one or more members of the adiponutrin family. The present invention is further directed to novel therapeutics and therapeutic targets for the intervention (treatment) and prevention of cardiovascular and metabolic disorders arising from dysregulated energy homeostasis, as related to one or more members of the adiponutrin family of proteins.

    Abstract translation: 本发明提供了鉴定具有与营养和/或能量内稳态相关的酶活性的多肽的方法，因此涉及一种或多种心血管和代谢疾病的发展，例如心血管疾病，肥胖症，胰岛素抵抗，2型 糖尿病，血脂异常，非酒精性脂肪性肝病和代谢综合征。 一种这样的方法包括鉴定多肽作为脂肪细胞蛋白家族的成员。 因此，本发明涉及属于脂肪调素素家族的多核苷酸和多肽，并且提供脂肪分泌素家族的新成员的新分离和纯化的多核苷酸和多肽，类似蛋白样磷脂酶结构域1（PNPLA1）。 还提供了使用与本发明相关或由本发明提供的多核苷酸和多肽用于筛选测试化合物（例如小分子，抗体等）以测试化合物检测和/或调节活性的能力的方法 脂肪蛋白家族蛋白的一个或多个成员。 本发明还涉及使用属于脂肪素家族的多核苷酸或多肽和/或脂肪素家族的一个或多个成员的调节剂来诊断，预测和监测至少一种心血管和代谢紊乱进展的新方法。 本发明进一步涉及用于干预（治疗）的新型治疗学和治疗靶标，以及与由脂肪蛋白家族蛋白质的一个或多个成员相关的由失调的能量稳态引起的心血管和代谢紊乱的预防。

    Methods and compositions comprising FATP5 for use in the diagnosis and treatment of metabolic disorders
    4.
    发明申请
    Methods and compositions comprising FATP5 for use in the diagnosis and treatment of metabolic disorders 审中-公开
    包含用于诊断和治疗代谢紊乱的FATP5的方法和组合物

    公开(公告)号：US20050054022A1

    公开(公告)日：2005-03-10

    申请号：US10919608

    申请日：2004-08-17

    Applicant: Ruth Gimeno ,  Brian Hubbard

    Inventor： Ruth Gimeno ,  Brian Hubbard

    IPC: C12N20060101 ,  C12Q1/25 ,  G01N33/53 ,  G01N33/537 ,  G01N33/543 ,  G01N33/68 ,  G01N33/92

    CPC classification number: G01N33/6893 ,  C12Q1/25 ,  G01N33/92 ,  G01N2333/9015 ,  G01N2500/04 ,  G01N2800/042 ,  G01N2800/044

    Abstract: The present invention provides methods for the identification of agents, e.g., therapeutic agents, that inhibit Fatty Acid Transport 5 (FATP5) activity, and methods of treating diseases or conditions associated with FATP5 function, e.g., obesity, insulin resistance, type 2 diabetes, dyslipidemia, fatty liver disease, and cardiovascular disease. Further aspects of the invention provide a transgenic FATP5 non-human knockout mammal, e.g., mouse, useful for elucidating the function of FATP5 in intact animals whose genomes comprise a wild-type FATP5 gene.

    Abstract translation: 本发明提供了用于鉴定抑制脂肪酸转运5（FATP5）活性的药剂，例如治疗剂的方法，以及治疗与FATP5功能相关的疾病或病症的方法，例如肥胖，胰岛素抵抗，2型糖尿病， 血脂异常，脂肪肝疾病和心血管疾病。 本发明的其它方面提供了转基因FATP5非人敲除哺乳动物（例如小鼠），其用于阐明在其基因组包含野生型FATP5基因的完整动物中FATP5的功能。

    GPAT3 encodes a mammalian, microsomal acyl-coa:glycerol 3- phosphate acyltransferase
    5.
    发明申请
    GPAT3 encodes a mammalian, microsomal acyl-coa:glycerol 3- phosphate acyltransferase 审中-公开
    GPAT3编码哺乳动物，微粒体酰基-CoA：甘油3-磷酸酰基转移酶

    公开(公告)号：US20080038278A1

    公开(公告)日：2008-02-14

    申请号：US11711577

    申请日：2007-02-26

    Applicant: Jingsong Cao ,  Ruth Gimeno ,  Jian-Liang Li

    Inventor： Jingsong Cao ,  Ruth Gimeno ,  Jian-Liang Li

    IPC: A61K39/395 ,  A61K31/7088 ,  C07K16/40 ,  C12Q1/48 ,  C12N5/00 ,  A61K38/00

    CPC classification number: C12Q1/48 ,  A61K31/7088 ,  A61K38/00 ,  C12N9/1029

    Abstract: The present invention provides isolated and purified polynucleotides and polypeptides related to mouse and human microsomal acyl-CoA:glycerol 3-phosphate acyltransferase 3 (GPAT3) and their uses in modulating triacylglycerol (TAG) levels in a cell or sample of interest. The invention also provides GPAT3 agonists and antagonists, e.g., GPAT3 polynucleotides and polypeptides, antibodies to GPAT3 (agonistic and antagonistic antibodies), GPAT3 inhibitory polypeptides, and GPAT3 inhibitory polynucleotides. The present invention is also directed to novel methods for diagnosing, prognosing, monitoring, treating, ameliorating and/or preventing conditions related to GPAT3, TAG synthesis (or accumulation), or the synthesis (or accumulation) of TAG precursors (e.g., MAG, LPA, PA, and/or G3P). These GPAT3-associated conditions include, but are not limited to, dyslipidemia (e.g., hyperlipidemia, hypertriglyceridemia, Type III hyperlipidemia), obesity, hypercholesterolemia, hepatic steatosis, cancer, skin disorders associated with altered lipid metabolism (e.g., acne vulgaris, dry skin), adiposity, type 2 diabetes (and complications associated therewith, such as dermopathy, retinopathy, neuropathy, and nephropathy), insulin resistance, hyperinsulinemia, hypertension, cardiovascular disease, atherosclerosis, stroke, thrombosis, lipodystrophy, lipopenia, Reye's syndrome, Cushing's syndrome, metabolic syndrome (e.g., syndrome X), eating disorders (e.g., anorexia, bulimia), skin homeostasis, disorders related to energy storage, nutrient absorption, and lipid metabolism, reduced or absent lactation, and low preterm birth weight (and complications thereof, such as defects in neural development).

    Abstract translation: 本发明提供与小鼠和人微粒体酰基辅酶A：甘油3-磷酸酰基转移酶3（GPAT3）相关的分离和纯化的多核苷酸和多肽及其在调节感兴趣的细胞或样品中的三酰基甘油（TAG）水平的用途。 本发明还提供GPAT3激动剂和拮抗剂，例如GPAT3多核苷酸和多肽，GPAT3抗体（激动剂和拮抗性抗体），GPAT3抑制性多肽和GPAT3抑制性多核苷酸。 本发明还涉及用于诊断，预后，监测，治疗，改善和/或预防与GPAT3相关的病症，TAG合成（或积累）或TAG前体的合成（或积累）的新方法（例如MAG， LPA，PA和/或G3P）。 这些GPAT3相关病症包括但不限于血脂异常（例如，高脂血症，高甘油三酯血症，III型高脂血症），肥胖症，高胆固醇血症，肝脂肪变性，癌症，与脂质代谢改变相关的皮肤病症（例如寻常痤疮，干性皮肤 ），肥胖，2型糖尿病（以及与其相关的并发症，如皮肤病，视网膜病变，神经病变和肾病），胰岛素抵抗，高胰岛素血症，高血压，心血管疾病，动脉粥样硬化，中风，血栓形成，脂肪营养不良，脂肪减少，雷氏综合征，库欣综合征 ，代谢综合征（例如综合征X），进食障碍（例如厌食症，贪食症），皮肤内稳态，与储能相关的疾病，营养吸收和脂质代谢，减少或不存在的泌乳，以及早产儿的体重（及其并发症） ，如神经发育缺陷）。

    Methods for the treatment of metabolic disorders, including obesity and diabetes
    9.
    发明申请
    Methods for the treatment of metabolic disorders, including obesity and diabetes 审中-公开

    公开(公告)号：US20060141520A1

    公开(公告)日：2006-06-29

    申请号：US11331549

    申请日：2006-01-13

    Applicant: Ruth Gimeno ,  Fong-Ying Tsai

    Inventor： Ruth Gimeno ,  Fong-Ying Tsai

    IPC: C12Q1/68

    CPC classification number: C12Q1/6883 ,  C07K14/705 ,  C07K14/723 ,  C12Q2600/156 ,  C12Q2600/158

    Abstract: The present invention relates to methods and compositions for the diagnosis and treatment of metabolic disorders, including, but not limited to, obesity, diabetes, overweight, anorexia, or cachexia. The invention further provides methods for identifying a compound capable of treating a metabolic disorder. The invention also provides methods for identifying a compound capable of modulating a metabolic activity. Yet further, the invention provides a method for modulating a metabolic activity. In addition, the invention provides a method for treating a subject having a metabolic disorder characterized by aberrant 14273 polypeptide activity or aberrant 14273 nucleic acid expression. In another aspect, the invention provides methods for modulating lipogenesis in a subject and methods for modulating lipolysis in a subject. In yet another aspect, the invention provides methods for regulating endogenous glucose levels.

Patent Agency Ranking